Belite Bio (BLTE) vs Erasca (ERAS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Erasca (ERAS) has outperformed Belite Bio (BLTE) over the past year, gaining 536.2% versus a gain of 95.4%. Belite Bio is the larger company by market cap ($6.20 billion vs $5.53 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | ERAS |
|---|---|---|
| Share price | $154.06 | $15.82 |
| Market cap | $6.20B | $5.53B |
| 1-day change | +1.01% | +2.33% |
| YTD return | -4.65% | +315.59% |
| 1-year return | +95.39% | +536.21% |
| 5-year return | — | -13.15% |
| Forward P/E | 68.17 | — |
| EPS (TTM) | $-2.74 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-77.61M | $-124.55M |
| 52-week high | $200.00 | $24.28 |
| 52-week low | $77.64 | $2.11 |
| Distance from 52-week high | -22.97% | -34.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +48.58% | +52.40% |
| Average volume | 179.38K | 4.37M |
| Shares outstanding | 40.27M | 349.76M |
| Employees | 41 | 103 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed BLTE by 440.8 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
BLTE vs ERAS FAQ
Which is bigger, Belite Bio or Erasca?
Belite Bio (BLTE) is larger, with a market capitalization of $6.20B compared with $5.53B for Erasca (ERAS).
Which stock has performed better over the past year, BLTE or ERAS?
ERAS returned +536.21% over the past 12 months, compared with +95.39% for BLTE (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Erasca in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.